Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAdV5-fib50
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- Gene Therapies
01
Overview
HAdV5-fib50 (also known as HAdV-5/fib50) is a replication-deficient, first-generation chimeric human adenovirus type 5 vector engineered with the fiber protein of adenovirus serotype 50. Developed as a gene transfer vector, it is primarily used in research to transduce human mesenchymal stem cells (hMSCs) and study cellular differentiation. Studies have shown that transduction with HAdV5-fib50 can stimulate the differentiation of bone marrow-derived mesenchymal stem cells (BM-MSCs) into pancreatic endocrine-like cells expressing insulin, glucagon, and somatostatin, or into adipocytes, demonstrating that these vectors are not biologically inert and can modulate host cell differentiation pathways.
- Other names
- HAdV-5/fib50-EF1α-DsRedhuman adenovirus type 5 fibers 50
02
Targets
CD46 (CD46 Molecule)
Beyond the preview
Go deeper on HAdV5-fib50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAdV5-fib50.